Revenue
2022
2023
2024
2025
bioAffinity Technologies, Inc. (BIAF)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $2.5M | $4,803 | — |
| Gross profit | — | — | — | $4,336 | — |
| Research & development | $1.4M | $1.5M | $1.5M | $1.4M | $1.0M |
| Operating expenses | $16.7M | $18.3M | $10.5M | $4.0M | $2.2M |
| Operating income | −$10.6M | −$9.0M | −$8.0M | −$4.0M | −$2.2M |
| EBITDAderived | −$10.1M | −$8.3M | −$7.7M | −$4.0M | −$2.2M |
| Net income | −$14.9M | −$9.0M | −$7.9M | −$8.2M | −$6.3M |
| Basic EPSper diluted share | -$8.66 | -$22.50 | -$0.91 | -$1.81 | -$2.36 |
| Diluted EPSper diluted share | -$8.66 | -$22.50 | -$0.91 | -$1.81 | — |